We did not observe a relationship between BAFF, IgG and IgM levels with infection rates over the previous 2 years in the ocrelizumab group, even when duration of ocrelizumab exposure was included as a covariate (Supplementary Fig. 4). This evidence concerns the gene CD40LG and infection.